Abstract Presentations to Watch at the 2019 Oncology Annual Meeting

ctDNA-for-CRC-recurrence-prognosisOver the next five days, more than 39,000 oncology professionals from around the world will gather at McCormick Place Convention Center in Chicago, Illinois, United States, for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. During this intensive, 5-day conference, experts across multiple tumor types will discuss state-of-the-art multidisciplinary treatments, topics of controversy, latest clinical trial updates, and new research findings. More than 2400 scientific abstracts have been selected for presentation at the meeting during oral sessions, clinical science symposia, and poster sessions. For this year’s ASCO meeting, a theme of “Caring for Every Patient, Learning From Every Patient” has been selected by the current ASCO president, Monica Bertignolli, MD, FACS, FASCO, to reflect the importance of providing the highest quality of care for every patient with cancer.

As in previous years, the prIME Lines team has identified several studies across various tumor types that have the potential to impact clinical practice or provide important answers to unresolved questions. Please stay tuned throughout the summer as we bring you more comprehensive coverage from some of these and other interesting trials presented at the 2019 ASCO Annual Meeting.

Breast Cancer

Abstract #1000—SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)
Rugo HS, et al | Oral session; Breast Cancer (Metastatic), Tuesday, June 4 from 9:45 AM to 9:57 AM, Hall D1

 Abstract #1002—Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial
Saura C, et al | Oral session; Breast Cancer (Metastatic), Tuesday, June 4 from 10:09 AM to 10:21 AM, Hall D1

 Abstract LBA1008—Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results
Hurvitz S, et al | Oral session; Breast Cancer (Metastatic), Tuesday, June 4 from 11:57 AM to 12:09 PM, Hall D1

 Abstract #1005—Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial
Junes RH, et al | Oral session; Breast Cancer (Metastatic), Tuesday, June 4 from 11:09 AM to 11:21 AM, Hall D1

 

Gastrointestinal Cancers

Abstract #LBA4—Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial
Kindler HL, et al | Plenary Session: Sunday, June 2 from 3:15 PM to 3:30 PM, Hall B1

Abstract #4000—APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma
Tempero M, et al | Oral session; Gastrointestinal (Noncolorectal), Sunday, June 2 from 9:45 AM to 9:57 AM, Arie Crown Theater

Abstract #LBA4007—Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study
Tabernero J, et al | Oral session; Gastrointestinal (Noncolorectal), Sunday, June 2 from 11:57 AM to 12:09 PM, Arie Crown Theater

 

Genitourinary Cancer

Abstract #LBA2—Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial
Sweeney C, et al | Plenary session: Sunday, June 2 from 2:15 PM to 2:30 PM, Hall B1

 

Gynecologic Cancer

Abstract #5505—Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24
Mirza MR, et al | Oral session; Gynecologic cancer, Monday, June 3 from 3:03 PM to 3:15 PM, S406

  

Head and Neck Cancer

Abstract #6000—Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Rischin D, et al | Oral session; Head and neck cancer, Friday, May 31 from 2:45 PM to 2:57 PM, E450

Abstract #6002—TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Guigay J, et al | Oral session; Head and neck cancer, Friday, May 31 from 3:09 PM to 3:21 PM, E450

 

 Lung Cancer

Abstract #9000—RELAY: A multinational, double-blind, randomized phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).
Nakagawa K, et al | Oral session, lung cancer (NSCLC metastatic), Monday, June 3 from 8:00 AM to 8:12 AM, Hall B1

Abstract #9001—Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C)
Noronha V, et al | Oral session, lung cancer (NSCLC metastatic), Monday, June 3 from 8:12 AM to 8:24 AM, Hall B1

 

In addition to the above trials, which will hopefully clarify remaining questions regarding the front-line management of advanced EGFR-mutant NSCLC, new data will be presented from several phase I/II clinical trials studying targeted therapies for NSCLC with rare driver mutations, such as MET alterations (abstract #9004 capmatinib and abstract #9005 tepotinib) and RET fusions (abstract #9008 BLU-667).

 

Hematologic Malignancies

Abstract #8001—E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma
Lonial S, et al | Oral session (Plasma cell dyscrasia): Sunday, June 2 from 9:57 AM to 10:09 AM, E451

 

Abstract #8003 —Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results
Moreau P, et al | Oral session (Plasma cell dyscrasia): Sunday, June 2 from 10:45 AM to 10:57 AM, E451

 

Abstract #8004—A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM)
Richardson PG, et al | Oral session (Plasma cell dyscrasia): Sunday, June 2 from 10:57 AM to 11|09 AM, E451